Pfizer Inc. (PFE)
Health Care21 articles
Price chart
Why is PFE moving today?
+0.5%PFE is +0.5% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 7 hours ago
Pfizer Inc. (PFE) overview
Pfizer is one of the world’s largest pharmaceutical companies, developing vaccines and medicines across many therapeutic areas.
PFE is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Pfizer Inc. trades on the NYSE under the ticker symbol PFE. The most recent market data puts the share price at about $29.58. That is up 0.48% on the session. At that price the company is worth roughly $168.60B.
Over the past 52 weeks, PFE has traded between $23.62 and $29.88. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 38.9. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns. PFE also pays a dividend. It yields around 5.84% at the current price.
Key statistics
Source: Yahoo Finance - quote as of 7 hours ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch PFE
PFE is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each PFE story as it breaks, and tags it bullish, bearish or neutral.
Size matters here as well. The S&P 500 is weighted by market value. PFE is large enough that its own share price nudges the whole index. So it is worth watching even for investors who only hold index funds.
What moves PFE
- Earnings. PFE reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from PFE.
- Sector news. Health Care stocks often move together, so a rival's news can move PFE too.
- Index weight. PFE is big enough to move the S&P 500 on its own.
Market Mood
Latest PFE news
Pfizer (PFE) and Moderna patent case against Bayer dismissed
Pfizer (PFE), BioNTech, and Moderna have lost their attempt to dismiss a patent infringement case brought by Bayer. The court's decision allows Bayer to pursue its claim related to the technology used in mRNA vaccines. This ruling may have implications for the patent landscape in the biopharmaceutical industry, potentially affecting how companies protect their innovations. The outcome could influence future litigation involving vaccine patents, which is valuable for investors in this sector.
Read More: Pfizer (PFE) and Moderna patent case against Bayer dismissed
Pfizer (PFE) Growth Strategy Discussed at U.S. All Stars Conference
Pfizer (PFE) discussed its growth strategies beyond COVID-19 at the U.S. All Stars Conference. The company emphasized shifting focus to immunology and rare diseases. This marks a strategic pivot as the demand for COVID-related products declines. Such a focus may represent an effort to sustain revenue streams as pandemic-related gains diminish.
Read More: Pfizer (PFE) Growth Strategy Discussed at U.S. All Stars Conference
Pfizer (PFE) to Share Drug Revenue with HHS Under Pricing Deal
Pfizer Inc. (PFE) will share a portion of its overseas drug revenue with the Department of Health and Human Services (HHS) as part of a pricing agreement. This agreement is aimed at ensuring that American taxpayers receive a fair return on drugs sold internationally. The specifics of the revenue-sharing percentage have not been disclosed, but it is expected to influence pricing strategies for medications. This matters for investors as it could affect Pfizer's revenue and profitability in the coming quarters.
Read More: Pfizer (PFE) to Share Drug Revenue with HHS Under Pricing Deal
Pfizer (PFE) Discusses Pipeline and AI Focus at Morgan Stanley
At the Morgan Stanley conference, Pfizer (PFE) highlighted its focus on pipeline advancements and artificial intelligence (AI) technologies. The company's strategy includes strengthening its presence in China, although no specific numbers or financial forecasts were provided. The emphasis on innovation and growth areas may impact investor confidence and future stock performance. Understanding Pfizer's initiatives could guide investors in assessing potential opportunities within the healthcare sector.
Read More: Pfizer (PFE) Discusses Pipeline and AI Focus at Morgan Stanley
Pfizer Stock Predictions for 2030: Future Trends Examined
The article discusses predictions regarding Pfizer's (PFE) stock performance by 2030. It highlights various analysts' outlooks, mentioning insights into market changes and how these could potentially impact Pfizer's position. While specific figures for projected stock prices are not provided, the importance of understanding market trends and their implications for investor strategies is emphasized. This analysis is crucial for investors looking to make informed decisions about their portfolios based on long-term forecasts for Pfizer.
Read More: Pfizer Stock Predictions for 2030: Future Trends Examined
Pfizer (PFE) Earnings Report Upcoming Amid Dividend Concerns
Pfizer (PFE) is set to release its earnings report soon, which will be closely scrutinized alongside its dividend and pipeline developments. Investors are particularly interested in how the company's performance in these areas may impact its stock value moving forward. The scrutiny reflects the ongoing uncertainties regarding Pfizer's pipeline projects and their potential revenue contributions. This earnings report will be significant for investors as it could influence market sentiment regarding Pfizer’s financial health and future growth prospects.
Read More: Pfizer (PFE) Earnings Report Upcoming Amid Dividend Concerns
Energy Transfer (ET) Offers 6.6% Yield Amid AI Growth Catalyst
Energy Transfer (ET) presents an investment opportunity with a forward dividend yield of 6.6%. The company is targeting 3% to 5% annualized distribution growth and has historically increased payouts by 2% to 4% annually. Meanwhile, Pfizer (PFE) features a nearly 7% forward dividend yield and trades at a low P/E ratio of 8.5. Despite some risks, the metrics indicate potential value for long-term investors in these stocks, appealing for those seeking reliable dividend returns.
Read More: Energy Transfer (ET) Offers 6.6% Yield Amid AI Growth Catalyst
Pfizer (PFE) Offers 6.9% Dividend Yield Amid New Drug Development
Pfizer (PFE) has been identified as a solid dividend stock, currently offering a forward-looking dividend yield of 6.9%. The company is focused on developing new profit centers, including acquiring Seagen in 2023 to enhance its oncology pipeline. By 2030, Pfizer anticipates launching at least eight new blockbuster drugs, supported by both acquisitions and internal development. This potential for new drugs reinforces Pfizer's ability to continue providing dividends, which is important for investors seeking steady income.
Read More: Pfizer (PFE) Offers 6.9% Dividend Yield Amid New Drug Development
Trump's Generic Drug Tariffs to Hit 100% by August 2028
President Donald Trump announced that generic drugs imported into the U.S. will face a 100% tariff starting in August 2028, rising to 200% in August 2029, after an initial two-year period with zero tariffs beginning August 1, 2026. This phased tariff schedule aims to incentivize domestic production of generic drugs. The U.S. imports nearly 50% of its generics from India, which significantly relies on the U.S. market for pharmaceutical exports. Ordinary investors should monitor these changes as they may impact the profitability and operations of major drugmakers like Eli Lilly and Pfizer (PFE).
Read More: Trump's Generic Drug Tariffs to Hit 100% by August 2028
Pfizer (PFE) Trades at 8x Earnings, Seagen Integration Drives Growth
Pfizer (PFE) trades at 8x forward earnings and has a 7% dividend yield, positioning it as a cheaper option compared to Amgen's (AMGN) 17x rebuild multiple. In Q1 2026, Pfizer's oncology franchise generated $3.83 billion in revenue, a 9% year-over-year increase, driven by its Seagen deal and Padcev, which contributed $591 million, up 39%. In contrast, Amgen's key products saw significant declines, with Prolia down 34% and Enbrel down 37%. This dissonance in performance highlights the contrasting strategies, where Pfizer is monetizing existing assets while Amgen is working on rebuilding growth, impacting investor sentiment toward both companies.
Read More: Pfizer (PFE) Trades at 8x Earnings, Seagen Integration Drives Growth
Pfizer (PFE) Offers Attractive Dividend Yield for Investors
Pfizer (PFE) is recognized for its dividend payouts, appealing to income investors. The current dividend yield is noted to be an attractive feature for those seeking steady income streams. Pfizer's financial performance, specifically regarding its earnings per share, is expected to influence investor sentiment positively. This focus on dividends might impact its stock valuation as investors look for reliable income sources amidst market fluctuations.
Read More: Pfizer (PFE) Offers Attractive Dividend Yield for Investors
PFE and JNJ Annual Dividend Income of $3,540 for Investors
Investors holding 500 shares each of Pfizer (PFE) and Johnson & Johnson (JNJ) can expect an annual passive income of $3,540 on a $127,000 investment, with a blended yield of 2.79%. JNJ recently increased its quarterly dividend to $1.34, marking its 64th consecutive increase, supported by a AAA-rated balance sheet and $19.7 billion in free cash flow. Meanwhile, PFE's yield stands at 6.8%, reflecting stock compression. JNJ reported Q1 2026 revenues of $15.426 billion in pharmaceuticals, an 11.2% year-over-year increase, while MedTech revenue reached $8.636 billion, up 7.7%.
Read More: PFE and JNJ Annual Dividend Income of $3,540 for Investors
Pfizer (PFE) Stock Price Drops Over 50% Since Pandemic Peak
Pfizer (PFE) has experienced a stock price decline of over 50% since its peak during the COVID-19 pandemic. This significant drop is attributed to market adjustments after expectations of ongoing vaccine needs did not materialize, leading to decreased investor confidence. Additionally, Pfizer faces challenges with upcoming patent expirations through 2028 and has struggled to develop new drugs to replace those losing patent protection. The company’s recent decision to acquire a competitor with a promising GLP-1 drug may impact future growth prospects.
Read More: Pfizer (PFE) Stock Price Drops Over 50% Since Pandemic Peak
Pfizer (PFE) Analysts Show Caution Amid 50% Stock Decline
Currently, only 2 out of 29 analysts rate Pfizer (PFE) as strong buy, while over 60% suggest a cautious outlook with ratings of hold, underperform, or sell. The stock has declined more than 50% from its 2021 peak. Patent expirations for key drugs like Eliquis and Vyndaqel are expected to impact revenues significantly by 2028. Despite these challenges, Pfizer maintains a dividend yield of 6.6%, much higher than the market average of 1.1%. The company continues efforts in drug development, including acquiring a promising GLP-1 candidate after dropping its own.
Read More: Pfizer (PFE) Analysts Show Caution Amid 50% Stock Decline
Innovent (HK:1801) Shares Rise 10% After $10.5 Billion Pfizer Deal
Shares of Innovent Biologics (HK:1801) increased by 10% following a deal with Pfizer valued up to $10.5 billion for the development of oncology medicines. The agreement includes an upfront payment of $650 million and up to $9.85 billion in milestone payments. Innovent will collaborate on four global programs, co-commercializing in the U.S. and Europe while retaining rights in Greater China. These developments come as partnerships between biotech and pharmaceutical firms are critical in addressing oncology disease concerns globally.
Read More: Innovent (HK:1801) Shares Rise 10% After $10.5 Billion Pfizer Deal
Pfizer (PFE) Lacks Earnings Momentum According to Analyst Jim Cramer
Analyst Jim Cramer stated that Pfizer (PFE) does not have any current earnings momentum. This observation could indicate potential concerns regarding PFE’s future stock performance in the market. Without positive earnings momentum, investor confidence may decline, potentially affecting the stock's valuation. It is essential for investors to monitor PFE's earnings reports closely to gauge any changes in momentum.
Read More: Pfizer (PFE) Lacks Earnings Momentum According to Analyst Jim Cramer
Pfizer (PFE) Stock Down Over 50% from 2021 High Amid Challenges
Pfizer (PFE) stock is down over 50% from its 2021 high as demand for COVID vaccines decreases. The company is facing headwinds, including upcoming patent cliffs that could lead to revenue declines for key drugs. Despite this, Pfizer maintains a 6.4% dividend yield, with management stating that supporting the dividend is a key corporate goal. The company has taken steps to pivot towards GLP-1 weight-loss drugs and continues to develop its portfolio in oncology and migraine treatments, which could improve its market position in the future.
Read More: Pfizer (PFE) Stock Down Over 50% from 2021 High Amid Challenges
Pfizer (PFE) Receives FDA Approval for Veppanu Breast Cancer Drug
The FDA has approved Veppanu, a breast cancer pill developed by Pfizer (PFE) and Arvinas, for advanced cases. This approval is significant as it provides a new treatment option for patients in later stages of breast cancer, potentially impacting the market for cancer therapeutics. The details of its efficacy and safety profile are yet to be published but could influence investor sentiment and market dynamics in the pharmaceutical sector. The new drug's launch may bolster Pfizer's pipeline and revenue streams in oncology.
Read More: Pfizer (PFE) Receives FDA Approval for Veppanu Breast Cancer Drug
Bristol Myers (BMY) Q1 profits rise 4% with $11.49 billion revenue
Bristol Myers Squibb (BMY) reported Q1 adjusted earnings of $1.58 per share, exceeding analysts' expectations of $1.42, with revenue of $11.49 billion also surpassing the forecast of $10.9 billion. Eliquis, partnered with Pfizer, generated $4.14 billion in sales, an increase of 16% year-over-year. Sales from the growth portfolio rose 12% to $6.23 billion, while sales of Opdivo fell 5% to $2.15 billion. The company reaffirmed its 2026 revenue outlook of $46.0 billion to $47.5 billion and adjusted earnings of $6.05 to $6.35 per share.
Read More: Bristol Myers (BMY) Q1 profits rise 4% with $11.49 billion revenue
Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
Pfizer (PFE) has reported positive results from its GLP-1 drug PF-08653944, which shows weight loss of 10% to 12% by week 28 in Phase 2b trials. This drug features a monthly injection regimen, compared to the weekly doses of competitors like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which may increase patient adherence. The weight loss drug market is projected to grow at nearly 25% annually through 2035, indicating strong competitive potential for Pfizer. As alternatives emerge, the dynamics of the anti-obesity drug market may be shifting, impacting shares of incumbents like NVO and LLY.
Read More: Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
Pfizer Seeks FDA Approval for Lyme Disease Vaccine with 70% Efficacy
Pfizer reported that its Lyme disease vaccine candidate demonstrated 70% efficacy in clinical trials. Despite this achievement, the vaccine missed a key statistical goal, which has raised concerns about its potential market impact. The company, along with its French partner Valneva, plans to pursue FDA approval even though low case numbers of Lyme disease contributed to the trial's challenges. This decision could signal significant developments in the vaccine market and impact future investor sentiment.
Read More: Pfizer Seeks FDA Approval for Lyme Disease Vaccine with 70% EfficacyMore Health Care stocks
Frequently asked questions
Is Pfizer Inc. in the S&P 500?
Yes. Pfizer Inc. trades as PFE and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is PFE in?
PFE sits in the Health Care sector of the S&P 500.
Where can I find the latest PFE news?
Right here. This page collects recent PFE news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Pfizer Inc.'s stock price?
PFE last traded at about $29.58. Prices move all through the session, so this is the latest quote rather than a live one.
What is Pfizer Inc.'s market cap?
PFE is worth roughly $168.60B. Market cap is the share price times the number of shares outstanding.
What is PFE's P/E ratio?
PFE trades at a trailing P/E ratio of about 38.9. The ratio compares the share price with earnings per share over the past year.